Clinical Research Directory
Browse clinical research sites, groups, and studies.
Patients With High-grade Pancreatic Neuroendocrine Tumors
Sponsor: National Cancer Center, Korea
Summary
* Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic chemotherapy is essential in cases with grade 3 pNETs or pNECs. * Cisplatin/etoposide remains the treatment of choice for high-grade pNET/pNEC. Other irinotecan-based therapies, such as FOLFIRI (cisplatin/irinotecan), FOLFOX, and temozolomide ± capecitabine, have been employed; however, a standard of care remains to be established.
Official title: Lurbinectedin as a Second-line Treatment for High-grade Pancreatic Neuroendocrine Tumors
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2025-09-23
Completion Date
2029-12-31
Last Updated
2025-10-01
Healthy Volunteers
No
Interventions
Lurbinectedin 4 MG Injection [Zepzelca]
Lurbinectedin shall be administered intravenously at a dose of 3.2 mg/m2 over 60 minutes every 21 days. The administration of the study drug shall be continued until disease progression or the occurrence of unacceptable toxicity.
Locations (1)
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea